Second‑Line Management of Treatment‑Resistant Depression and Anxiety

Treatment‑Modification Timeline

The American College of Physicians strongly recommends modifying therapy if there is inadequate response within 6–8 weeks of initiating treatment for major depressive disorder. [1][4]

Equivalence of second‑generation antidepressants – Moderate‑quality evidence shows no difference in response rates when switching from an SSRI to bupropion, sertraline, or venlafaxine. [2][5]
Remission and severity – Low‑quality evidence indicates no difference in remission rates or depression severity among these switching options. [2][5]
Switching to cognitive therapy – Switching to cognitive therapy yields similar response and remission outcomes compared with switching to another medication. [2][3]5

Depression‑severity reduction – Augmentation with bupropion reduces depression severity more than buspirone, although response and remission rates are comparable. [6][2][3][7]
Adverse‑event discontinuation – Moderate‑quality evidence shows lower discontinuation due to adverse events with bupropion augmentation (≈12.5 %) versus buspirone (≈20.6 %). [2][3]
Cognitive‑therapy augmentation – Adding cognitive therapy to pharmacologic treatment provides similar efficacy to medication augmentation for response, remission, and severity. [2][3]5

Escitalopram + CBT – Low‑quality evidence finds no difference in overall discontinuation rates between escitalopram alone and escitalopram combined with telephone‑based CBT. [2][7]
Comorbid anxiety – For patients with concurrent anxiety, combining pharmacotherapy with psychotherapy may be especially beneficial, based on early‑treatment studies. 8

Initiate bupropion at a low dose while continuing escitalopram 20 mg daily. [2][3]
Monitor for serotonin‑syndrome symptoms; the risk is lower with bupropion than with many other augmentation agents. 9
Bupropion is linked to fewer sexual adverse events than SSRIs, potentially improving tolerability. 4

Sertraline, bupropion, and venlafaxine are interchangeable options for second‑step therapy, supported by moderate‑quality evidence. [2][5]

Begin regular assessment of therapeutic response and adverse effects within 1–2 weeks after any treatment modification. [1][4]
Specifically screen for emergent suicidal thoughts, agitation, or unusual behavioral changes. 4
After achieving a satisfactory response, continue treatment for 4–9 months; patients with recurrent depression may require longer maintenance. [1][4]

When contemplating citalopram as an alternative, monitor for QT‑interval prolongation; escitalopram carries a lower risk. 8